Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
  • Home
Article
  • Cited by 241

  • Access

Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)

  • Neil Fishman, Society for Healthcare Epidemiology of America, Infectious Diseases Society of America and Pediatric Infectious Diseases Society

Abstract

Antimicrobial resistance has emerged as a significant healthcare quality and patient safety issue in the twenty-first century that, combined with a rapidly dwindling antimicrobial armamentarium, has resulted in a critical threat to the public health of the United States. Antimicrobial stewardship programs optimize antimicrobial use to achieve the best clinical outcomes while minimizing adverse events and limiting selective pressures that drive the emergence of resistance and may also reduce excessive costs attributable to suboptimal antimicrobial use. Therefore, antimicrobial stewardship must be a fiduciary responsibility for all healthcare institutions across the continuum of care. This position statement of the Society for Healthcare Epidemiology of America, the Infectious Diseases Society of America, and the Pediatric Infectious Diseases Society of America outlines recommendations for the mandatory implementation of antimicrobial stewardship throughout health care, suggests process and outcome measures to monitor these interventions, and addresses deficiencies in education and research in this field as well as the lack of accurate data on antimicrobial use in the United States.

    •

      • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)
      Available formats
      ×

Copyright

COPYRIGHT: © The Society for Healthcare Epidemiology of America 2012

Corresponding author

University of Pennsylvania Health System, 3400 Spruce Street, Penn Tower, Suite 101, Philadelphia, PA 19104 (neil.fishman@uphs.upenn.edu)

References

Hide All
1. Penicillin finder assays its future. New York Times. 26 June 1945:21.
2. Spink, WW, Ferris, V. Quantitative action of penicillin inhibitor from penicillin-resistant strain of Staphylococcus . Science 1945; 102:221–223.
3. Barrett, FF, McGehee, RF, Finland, M. Methicillin-resistant Staphylococcus aureus at Boston City Hospital. N Engl J Med 1968; 279:441–448.
4. Centers for Disease Control and Prevention NNIS System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000; issued June 2000. Am J Infect Control 2000;28:429–448.
5. Herold, BC, Immergluck, LC, Maranan, MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593–598.
6. Naimi, TS, LeDell, KH, Como-Sabetti, K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976–2984.
7. Deleo, FR, Otto, M, Kreisworth, BN, Chambers, HF. Community-associated meticillin-resistant Staphylococcus aureus . Lancet 2010;375:1557–1568.
8. Lynch, JP 3rd, Zhanel, GG. Streptococcus pneumoniae, epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010;16:217–225.
9. Deguchi, T, Nakane, K, Yasuda, M, Maeda, S. Emergence and spread of drug resistant Neisseria gonorrhoeae . J Urol 2010;184:851–858.
10. Parry, CM, Threlfall, EJ. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr Opin Infect Dis 2008;21:531–538.
11. Jacobson, KR, Tierney, DB, Jeon, CY, Mitnick, CD, Murray, MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010;51:6–14.
12. Bonten, MJ, Willems, R, Weinstein, RA. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001;1:314–325.
13. Chavers, LS, Moser, SA, Benjamin, WH, et al. Vancomycin-resistant enterococci: 15 years and counting, J Hosp Infect 2003; 53:159–171.
14. Hiramatsu, K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001;1:147–155.
15. Nordmann, P, Cuzon, G, Naas, T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228–236.
16. Ho, J, Tambyah, PA, Paterson, DL. Multiresistant gram-negative infections: a global perspective. Curr Opin Infect Dis 2010;23:546–553.
17. Oteo, J, Pérez-Vázquez, M, Campos, J. Extended-spectrum beta-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 2010;23:320–326.
18. Garnacho-Montero, J, Amaya-Villar, R. Multiresistant Acineto-bacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010;23:332–339.
19. Zavascki, AP, Carvalhaes, CG, Picāo, RC, Gales, AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010;8:71–93.
20. Falagas, ME, Rafailidis, PI, Matthaiou, DK, Virtzili, S, Nikita, D, Michalopoulos, A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008;32:450–454.
21. Chen, LF, Chopra, T, Kaye, KS. Pathogens resistant to antibacterial agents. Infect Dis Clin N Am 2009;23:817–845.
22. Rice, LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 2009;12:476–481.
23. Boucher, HW, Talbot, GH, Bradley, JS, et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1–12.
24. Lautenbach, E, Weiner, MG, Nachamkin, I, Bilker, WB, Sheridan, A, Fishman, NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006;27:893–900.
25. Roberts, RR, Hota, B, Ahmad, I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009;49:1175–1184.
26. Patel, G, Huprikar, S, Factor, SH, Jenkins, SG, Calfee, DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099–1106.
27. Filice, GA, Nyman, JA, Lexau, C, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol 2010;31:365–373.
28. Mauldin, PD, Saigado, CD, Hansen, IS, Durup, DT, Bosso, JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 2010;54:109–115.
29. Infectious Diseases Society of America. The 10 × 20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50:1081–1083.
30. Infectious Diseases Society of America. Antimiaobial resistance. http://www.idsociety.org/AR_Policy/. Accessed October 27, 2010.
31. Shlaes, DM, Gerding, DN, John, JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275–291.
32. Shlaes, DM, Gerding, DN, John, JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584–599.
33. Dellit, TH, Owens, RC, McGowan, JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159–177.
34. Spellberg, B, Blaser, M, Guidos, RJ, et al for the Infectious Diseases Society of America. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011;52(suppl 5): S397–S428.
35. Department of Health and Human Services. HHS action plan to prevent healthcare-associated infections, http://www.hhs.gov/ash/initiatives/hai/actionplan/index.html. Accessed October 27, 2010.
36. Gilbert, DN, Spellberg, B, Bartlett, JG for the Infectious Diseases Society of America. Position paper: an unmet medical need: rapid molecular diagnostic tests for respiratory tract infections. Clin Infect Dis 2011;52(suppl 4):S384–S395.
37. Gilbert, DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010;48:2325–2329.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed